Abstract: The present invention relates to the use of an oral composition comprising yeast extract, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as Clostridium difficile. Such effects may include the failure of the integrity of the gut epithelial cells and diarrhoea as well as other COX-2 mediated effects.

Abstract: A nutritional composition comprising a specific essential oil and/or specific pure compound isolated from the essential oil for prevention or treatment of infection by an Helicobacter-like organism, a method of production of the composition, use of the composition in the manufacture of a functional food or medicament for the prevention or treatment of infection by an Helicobacter-like organism and a method of treatment of infection by an Helicobacter-like organism which comprises consumption or administration of a functional food or medicament comprising an effective amount of the composition.

Abstract: The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophtalmological applications, a food or petfood compostiion for modulating bacterial colonisation, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The invention also relates to lipoteichoic acid selected thereof.

Abstract: The present invention concerns an adherence gene from Helicobacter pylori, a polypeptide coded thereby and antibodies against the polypeptide.

Abstract: At least one strain of lactic bacteria and/or one of its metabolites or a medium fermented by at least one lactic bacteria that have been isolated and selected for its ability to display a strong anti-Helicobacter bactericidal activity in vitro, are utilized for the preparation of a composition intended for the prophylaxis or the treatment of disorders related to GHLO infections in pets. Also, pet food compositions containing the same.

Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection and treatment of Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.

Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection and treatment of Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.

Abstract: The present invention concerns an adherence gene from Helicobacter pylori, a polypeptide coded thereby and antibodies against the polypeptide.

Abstract: A poly-3-hydroxybutyrate metabolic pathway essential for Helicobacter pylori survival in a host is provided. A novel Helicobacter pylori Coenzyme A transferase (Hp CoA-t), thiolase and PHB synthase as well as methods for their preparation and use are provided. Hp CoA-t and thiolase polynucleotides and proteins are provided as well as detection and preparative methods using such molecules. Methods for the determination of a propensity to develop gastritis, peptic ulcer disease, or gastric cancer is provided for by detection methods. Methods are also provided for the use of Hp CoA-t, thiolase or PHB synthase proteins and fragments retaining enzymatic activity in the identification of potential drug candidates for the treatment of some types of gastric disease. Pharmaceutical compositions containing Hp CoA-t protein fragments, antisense nucleic acids or other inhibitors of Hp CoA-t, thiolase and PHB synthase as well as methods for their use in the treatment of some types of gastric disease are also provided.

Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.